Shamburg News · 8-K filed Nov 17, 2026, 4:50 PM EST
Aldeyra Therapeutics Receives Nasdaq Notice of Minimum Bid Price Deficiency
ALDX · Aldeyra Therapeutics, Inc.
- Other event
- Delisting
- Materiality: high
On November 17, 2026, Aldeyra Therapeutics received a Nasdaq letter stating that the closing bid price of its common stock was below the $1.00 minimum for 30 consecutive business days, failing Nasdaq's Minimum Bid Price Requirement. The notice has no immediate effect on the listing, which remains fully effective on The Nasdaq Capital Market. The company has an initial compliance period of 180 calendar days, until May 17, 2027, to regain compliance and may be eligible for an additional 180-day period.
Source: SEC EDGAR, Form 8-K, Item 3.01, accession 0001193125-26-465667.
Written from the filing by Shamburg Markets. Figures are as reported by the company.